REVIEW

Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers

David S. Lawrence\(^1,2\)*, Tshepo Leeme\(^1\), Mosepele Mosepele\(^1,3\), Thomas S. Harrison\(^4,5\), Janet Seeley\(^2,6\), Joseph N. Jarvis\(^1,2\)

\(^1\) Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, \(^2\) Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, \(^3\) University of Botswana, Gaborone, Botswana, \(^4\) Institute for Infection and Immunity, St George’s University of London, and St George’s University Hospitals NHS Foundation Trust, London, United Kingdom, \(^5\) MRC Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom, \(^6\) MRC/UVR & LSHTM Uganda Research Unit, Entebbe, Uganda

* david.s.lawrence@lshtm.ac.uk

Abstract

Background

It is essential that clinical trial participants are representative of the population under investigation. Using HIV-associated cryptococcal meningitis (CM) as a case study, we conducted a systematic review of clinical trials to determine how inclusive and representative they were both in terms of the affected population and the involvement of local investigators.

Methods

We searched Medline, EMBASE, Cochrane, Africa-Wide, CINAHL Plus, and Web of Science. Data were extracted for 5 domains: study location and design, screening, participants, researchers, and funders. Data were summarised and compared over 3 time periods: pre-antiretroviral therapy (ART) (pre-2000), early ART (2000 to 2009), and established ART (post-2010) using chi-squared and chi-squared for trend. Comparisons were made with global disease burden estimates and a composite reference derived from observational studies.

Results

Thirty-nine trials published between 1990 and 2019 were included. Earlier studies were predominantly conducted in high-income countries (HICs) and recent studies in low- and middle-income countries (LMICs). Most recent studies occurred in high CM incidence countries, but some highly affected countries have not hosted trials. The sex and ART status of participants matched those of the general CM population. Patients with reduced consciousness and those suffering a CM relapse were underrepresented. Authorship had poor representation of women (29% of all authors), particularly as first and final authors. Compared to trials conducted in HICs, trials conducted in LMICs were more likely to include female authors.
(32% versus 20%, \( p = 0.014 \)) but less likely to have authors resident in (75% versus 100%, \( p < 0.001 \)) or nationals (61% versus 93%, \( p < 0.001 \)) of the trial location.

**Conclusions**

There has been a marked shift in CM trials over the course of the HIV epidemic. Trials are primarily performed in locations and populations that reflect the burden of disease, but severe and relapse cases are underrepresented. Most CM trials now take place in LMICs, but the research is primarily funded and led by individuals and institutions from HICs.

**Author summary**

It is essential that clinical trial participants are representative of the population under investigation. Similarly, research must meaningfully include researchers who are from and/or based in the location where the study is being conducted, both to ensure that the research matches the local need but also to promote equity in research. Using clinical trials in HIV-associated cryptococcal meningitis as a case study, we conducted a systematic review to determine how inclusive and representative trials have been across the course of the HIV epidemic. We identified 39 studies. There was a geographical shift with trials moving from the USA to Africa and Asia over time. We found that recent trials were conducted in areas heavily affected by cryptococcal meningitis, but we did identify geographical areas and patient groups that have been underrepresented. We also found inequality within authorship that was skewed towards male researchers from high-income countries. These findings outline areas for our discipline to focus on. We can also use this study as a benchmark from which to monitor our progress over time. This is a broad methodology that could be adopted and adapted by other research groups.

**Introduction**

Global health research is a rapidly expanding and evolving field, and global health practitioners are increasingly reflecting on the ethos and equity of research [1–3]. Concerns have been raised that clinical trials are disproportionately conducted in a limited number of countries [4–7] and that individual researchers and institutions from high-income countries (HICs) disproportionately benefit from global health research [8], leading to calls to examine and potentially reform how global health research is conceptualised and conducted.

The emergence of the HIV epidemic was a catalyst for huge investment in global health, both in terms of research and service provision [9]. This expansion in investment led to the creation of a large number of transnational research partnerships (TRPs), whereby institutions in HICs partnered with those in low- and middle-income countries (LMICs) to collaborate on research studies [10]. As a consequence, an increasing number of research publications in the field of HIV are published each year, and the number of countries contributing to HIV research continues to grow [11]. This research has contributed to dramatic reductions in the number of new infections and deaths due to HIV over the last 30 years. Despite this, an estimated 1,700,000 people were newly infected with HIV, and 690,000 AIDS-related deaths occurred in 2019 [12], with sub-Saharan Africa at the centre of the epidemic. There remains a clear need for further research in prevention, treatment, and implementation. Ongoing research needs to be appropriate to the research setting, address high-priority research...
questions [13], and include representative patient populations in order to generate applicable and generalisable findings [14].

In addition to ensuring that research participants are representative of the general population suffering from a disease, it is equally important to ensure that the researchers and institutions involved are representative of where the disease burden lies. At present, the majority of HIV funding comes from HICs [9], and therefore, the resources (both economic and human) flow from HICs to LMICs. Individuals and institutions from HICs lead the research, and researchers from LMICs are often found in the middle of author lists or excluded altogether from publications arising from African health research [15]. Inclusive research teams are essential to shape priorities and develop studies based on an in-depth understanding of the local context and inclusive representation will promote fairness, strengthen capacity, and ensure the future sustainability of research.

Cryptococcal meningitis (CM) remains a significant contributor to AIDS-related mortality in LMICs despite expanding rollout of effective antiretroviral therapy (ART) [16,17]. Annual global deaths from CM are estimated at 181,000, and CM is responsible for 15% of all AIDS-related deaths [18]. Over the past 30 years, clinical trials have defined treatment strategies that have led to a dramatic reduction in 10-week mortality rates from almost 100% to approximately 30% to 40% [19–21], but further clinical trials remain essential to further improve mortality outcomes and develop treatments appropriate for LMICs. Using CM as a case study, we performed a systematic review to examine how representative and inclusive CM clinical trials have been over the course of the HIV epidemic. Our aim was to describe the location of CM trials and the characteristics of those enrolled in order to perform a comparison with the current epidemiology. We also aimed to describe the gender, location, and nationality of researchers involved in CM trials.

**Methods**

We included any trial in which individuals with HIV-associated CM were randomly assigned to 1 of at least 2 intervention arms. The intervention could be any treatment for their condition, and there was no restriction on the nature of the comparator arm. Our focus was on the characteristics of individuals who were recruited into the trials and the researchers conducting the studies, and not on trial outcomes.

**Search method and data collection**

We searched for studies published up to 4 March 2020 using Medline, EMBASE, Cochrane Library, Africa-Wide, CINAHL Plus, and Web of Science. We also searched ClinicalTrials.gov for completed and published trials. Our search strategy combined terms related to HIV-associated CM and clinical trials (see Table 1A). No restrictions were placed on language. We excluded studies related to CM that was not associated with HIV or where data from HIV-infected individuals could not be extracted, observational studies, healthy volunteer studies recruiting participants with previously treated CM, studies without comparator arms, manuscripts where data were presented elsewhere in a primary manuscript, and nonoriginal research articles such as editorials. The search strategy and protocol were developed by the authors prior to commencing the search and were registered with PROSPERO (CRD42020171845).

All papers were entered into Covidence [22]. Duplicates were removed and then titles and abstracts were independently screened against the eligibility criteria by DSL and TL. Noneligible studies were removed, and the full texts of potentially eligible titles were assessed for
inclusion. JNJ and MM adjudicated in the case of any conflict regarding study inclusion. The reference lists of included studies were searched to identify any additional eligible studies.

**Data extraction**

We extracted the relevant variables from each included paper (Table 1B) in 5 key domains: Study location and design, screening, participants, researchers, and funders. If necessary, the authors of an article were contacted for information that may not have been presented in the final publication. Researcher data were augmented by online searches of institutional web-pages and profiles on sites such as LinkedIn and Research Gate. If gender data could not be confidently elicited, then the gender of authors was determined using a website called Genderize.io that predicts the gender of a person given their name. Either DSL or TL performed the data extraction and then the other verified the data. Any discrepancies were discussed and resolved.

**Data synthesis and analysis**

Data were summarised using descriptive statistical analysis. To describe the geography of where participants were recruited, the locations of trial sites were analysed individually and also grouped into World Bank Regions. To demonstrate trends over time, comparison was made over 3 different periods: pre-2000, 2000 to 2009, and post-2010 to broadly demonstrate the pre-widespread ART era, early ART era, and established ART era, respectively. The end date of recruitment was used to determine within which of these time periods the study would be categorised. In papers where the specific months of recruitment were not stated, the year of publication was used. Where data could not be extracted for individual sites within multicountry trials, these numbers were averaged. We compared the characteristics of trial participants (gender, relapse rate, ART status, and baseline Glasgow Coma Scale (GCS)) to a composite...
reference of recently published observational and surveillance data from routine care settings [16,23–26]. ART experienced was defined as being on ART at the time of randomisation, including individuals who were on zidovudine monotherapy prior to the availability of combination ART. Chi-squared testing for trend was performed to describe trends in the demographics of trial participants and researchers over time. With regard to the gender, countries where researchers were born and where they resided during the trial, each study was categorised as either taking place in HICs or LMICs, and chi-squared calculations allowed comparison between these 2 groups. Statistical analysis was conducted in Stata/SE 15.0.

Results
The initial database search yielded 1,040 studies (Fig 1), of which 291 were duplicates. A total of 749 titles and abstracts were reviewed, with 65 selected for full-text review. Of these, 26 were excluded. No additional studies were identified after reviewing the reference lists of included studies. A total of 39 studies were included in the final data analysis (Table 2).

Study design and location
We identified 39 trials that recruited a total of 5,056 participants between 1985 and 2017 and were published between 1990 and 2019 (Table 3). Fig 2 highlights the location and number
Table 2. A summary of the 39 included studies.

| Study            | Title                                                                 |
|------------------|----------------------------------------------------------------------|
| Larsen 1990 [27] | Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. |
| Bozzette 1991 [28] | A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. |
| deGans 1992 [29] | Itraconazole compared with amphotericin B plus fluycytosine in AIDS patients with cryptococcal meningitis. |
| Saag 1992 [30]   | Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. |
| Powderly 1992 [31] | A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. |
| Sharkey 1996 [32] | Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. |
| Joly 1996 [33]   | Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. |
| Leenders 1997 [34] | Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. |
| Chotmongkol 1997 [35] | Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and fluycytosine in the treatment of cryptococcal meningitis in AIDS. |
| Van der Horst 1997 [36] | Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. |
| Mayanja-Kizza 1998 [37] | Combination therapy with fluconazole and fluycytosine for cryptococcal meningitis in Ugandan patients with AIDS. |
| Saag 1999 [38]   | A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. |
| Newton 2002 [39] | A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. |
| Vibhagool 2003 [40] | Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. |
| Mootsikapun 2003 [41] | The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. |
| Pappas 2004 [42] | Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. |
| Brouwer 2004 [43] | Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. |
| Chotmongkol 2005 [44] | Initial treatment of cryptococcal meningitis in AIDS. |
| Tansuphasawadikul 2006 [45] | Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. |
| Techapornroong 2007 [46] | Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial. |
| Milefchik 2008 [47] | Fluconazole alone or combined with fluycytosine for the treatment of AIDS-associated cryptococcal meningitis. |
| Bicanic 2008 [48] | High-dose amphotericin B with fluycytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. |
| Pappas 2009 [49] | A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. |
| Nussbaum 2010 [50] | Combination fluycytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. |
| Makadzange 2010 [51] | Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. |
| Jadhav 2010 [52] | Liposomal amphotericin B (FungisomeTM) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: A multicentric, randomized controlled trial |

(Continued)
of participants that were recruited into clinical trials during the different time periods and presents this in comparison with data from the comprehensive 2014 global burden of disease estimates highlighting the 12 countries with the largest annual number of incident cases [18]. During the 30 years covered by this review, trials have moved from predominantly being conducted in the United States of America to sub-Saharan Africa where 75% of all CM trial participants were recruited since 2010. Only 43 patients from Europe and Central Asia have been recruited into a CM trial. The majority (n = 29 (74%)) focused on induction therapy for CM. Primary outcomes were initially centred around clinical and microbiological markers, but in recent years, there has been an increasing trend towards mortality being the primary outcome. The majority (n = 38 (97%)) of trials only included HIV–infected patients and, where data were available, 20/24 (83%) trials only permitted the inclusion of patients suffering from a first episode of CM and 9/20 (45%) permitted only ART-naïve patients to be included. No studies specifically stated that pregnant or lactating women could be included but 30 (77%) and 23 (59%) studies, respectively, explicitly excluded these populations.

### Screening and randomisation

Screening data were not available for all studies but were reported more thoroughly in recently published papers. Out of 18 papers where data were available, a total of 5,011 potential participants were screened, and 2,763 (55%) were randomised. Seven percent of individuals that were approached declined consent, and this was consistent across time periods. There were 12 documented instances of a patient not being included due to pregnancy and 5 due to lactation. The majority of studies (n = 38 (97%)) reported data on those who were withdrawn due to

| Study                          | Title                                                                 |
|--------------------------------|-----------------------------------------------------------------------|
| Hamill 2010 [53]               | Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. |
| Loyse 2012 [54]               | Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. |
| Jarvis 2012 [55]              | Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. |
| Jackson 2012 [56]             | A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. |
| Day 2013 [57]                 | Combination antifungal therapy for cryptococcal meningitis.          |
| Bisson 2013 [58]              | Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. |
| Boulware 2014 [59]            | Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. |
| Vaidhya 2015 [60]             | Combination versus monotherapy for the treatment of HIV associated cryptococcal meningitis |
| Beardsley 2016 [21]           | Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. |
| Villanueva-Lozano 2018 [61]   | Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican centre experience. |
| Molloy 2018 [19]              | Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. |
| Rhein 2019 [62]               | Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial |
| Jarvis 2019 [63]              | Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial |

https://doi.org/10.1371/journal.pntd.0009376.t002
### Table 3. Characteristics of HIV-associated cryptococcal meningitis trials within different time periods and overall.

Where data were not available, the number of trials with available data is presented as a denominator.

| TRIAL DESIGN | PRE-2000 | 2000–2009 | 2010 ONWARDS | OVERALL N(%) |
|--------------|----------|-----------|--------------|--------------|
| Number of trials | 14       | 14        | 11           | 39           |
| Focus of trial | Induction | 10 (71%)  | 10 (71%)     | 9 (82%)      | 29 (74%)     |
|                | Maintenance | 3 (21%)   | 2 (14%)      | 0            | 5 (13%)      |
|                | ART timing | 0         | 1 (7%)       | 2 (18%)      | 3 (8%)       |
|                | Other      | 1 (7%)    | 1 (7%)       | 0            | 2 (5%)       |
| Primary outcome | Mortality | 0         | 1 (7%)       | 6 (55%)      | 7 (18%)      |
|                | Microbiological | 4 (29%)  | 7 (50%)     | 5 (45%)      | 16 (41%)     |
|                | Clinical   | 3 (21%)  | 6 (43%)     | 0            | 9 (23%)     |
|                | Combined   | 7 (50%)  | 0           | 0            | 7 (18%)     |
| Inclusion | HIV infected only | 14 (100%) | 13 (93%)    | 11 (100%)    | 38 (97%)    |
|            | First episode only | 4/7 (57%) | 9/10 (90%)  | 7/7 (100%)   | 20/24 (83%) |
|            | ART naïve only | 0/5       | 5/6 (83%)  | 4/9 (44%)    | 9/20 (45%)  |

**SCREENING AND RANDOMISATION**

| Number of studies with data | 1 | 7 | 10 | 18 |
|-----------------------------|---|---|----|----|
| Number screened             | 42 | 965 | 4,004 | 5,011 |
| Number screened out         | 16 | 589 | 1,643 | 2,248 |
| % screen failures           | 38% | 61% | 41% | 45% |
| Screen failures             | Declined | 6 (14%) | 66 (7%) | 292 (7%) | 364 (7%) |
|                            | Pregnant  | 0 | 2 (0.2%) | 10 (0.2%) | 12 (0.2%) |
|                            | Lactating | 0 | 0 | 5 (0.1%) | 5 (0.1%) |
| Number randomised           | 1,814 | 797 | 2,455 | 5,066 |

**Withdrawal**

| Number of studies with data | 13 | 14 | 11 | 38 |
|-----------------------------|---|---|----|----|
| Number randomised           | 1,759 | 797 | 2,455 | 5,011 |
| Late exclusion              | 132 (8%) | 26 (3%) | 50 (2%) | 208 (4%) |
| Withdrawal of consent       | 24 (1%) | 3 (0.4%) | 8 (0.3%) | 35 (1%) |
| Loss to follow-up           | 58 (3%) | 48 (6%) | 16 (0.7%) | 122 (2%) |

**PARTICIPANTS**

| Gender | Number of studies with data | 13 | 14 | 11 | 38 |
|--------|-----------------------------|---|---|----|----|
| Number male | 1,454 | 480 | 1,494 | 3,427 |
| Number female | 183 | 285 | 901 | 1,369 |
| % female | 11% | 37% | 38% | 29% |
| ART status | Number of studies with data | 7 | 9 | 9 | 25 |
| Number ART naïve | 906 | 594 | 1,196 | 2,696 |
| Number ART experienced | 288 | 11 | 889 | 1,188 |
| % ART experienced | 24% | 2% | 43% | 31% |

| Episode | Number of studies with data | 6 | 9 | 7 | 22 |
|---------|-----------------------------|---|---|---|----|
| Number first episode | 997 | 557 | 1,822 | 3,376 |
| Number relapse | 28 | 0 | 0 | 28 |
| % relapse | 3% | 0% | 0% | 1% |

| Baseline GCS | Number of studies with data | 8 | 9 | 9 | 26 |
|--------------|-----------------------------|---|---|---|----|
| Number GCS 15 | 765 | 410 | 1,654 | 2,829 |
| Number GCS <15 | 131 | 58 | 697 | 886 |
| % number GCS <15 | 15% | 12% | 30% | 24% |

ART, antiretroviral therapy; GCS, Glasgow Coma Scale.

*Statistically significant.

https://doi.org/10.1371/journal.pntd.0009376.t003
meeting an early withdrawal criteria \((n = 208/5,011 (4\%))\), withdrew their consent \((n = 35/5,011 (1\%))\), or were lost to follow-up \((n = 122/5,011 (2\%))\).

**Participants**

Data from 38/39 included studies demonstrated that 1,369/4,796 (29\%) of participants in CM trials were female (Fig 3). There was a significant increase over time in the proportion of female participants \((p < 0.0001)\). There was no report of any pregnant or lactating women being included in any clinical trial. A total of 1,188/3,884 (31\%) participants were ART experienced upon enrolment into the trial. The proportion of ART experienced participants fluctuated from 24\% prior to 2000 to 2\% between 2000 and 2009 and 43\% after 2010 demonstrating a general increase \((p < 0.0001)\). A total of 28/3,404 (0.8\%) participants were presenting with a relapse of CM, and these were all recruited prior to 2000. Twenty-four percent (886/3,715) of participants were recruited with a GCS < 15, indicating impaired decision-making capacity, and there was a trend for the proportion with reduced GCS to increase over time \((p < 0.0001)\).
Researchers

The median number of researchers named as authors on the primary manuscript was 11 (range 2 to 37), and 7 papers also had additional contributors listed within an appendix (Table 4). Of all named researchers, 29% were women. Overall, female researchers were underrepresented as first (26%), second (29%), third (19%), and final author (13%). No significant change was observed over time. Regarding whether named authors were resident in one of the research locations during the period of the study, this was case for the majority of first (95%), second (89%), and final (74%) authors. A total of 82% of all named authors were resident in one of the research locations, and there was a trend for this proportion to reduce over time ($p < 0.0001$). When comparing these same 3 domains by comparing studies that were conducted in HICs and LMICs, there were significantly more female authors on studies conducted in LMICs ($p = 0.014$). There were also significantly fewer named authors who were resident or nationals of research sites within trials conducted in LMICs ($p < 0.0001$ and $p < 0.0001$, respectively).

Table 4. Researcher data summarising the number, gender, country of residence, and nationality of named authors on the primary manuscript of HIV-associated cryptococcal meningitis clinical trials.

|                        | PRE-2000 | 2000–2009 | 2010 ONWARDS | OVERALL |
|------------------------|----------|-----------|--------------|---------|
| Number of papers       | 14       | 14        | 11           | 39      |
| Median number of authors (range) | 12 (3–17) | 8 (2–14) | 17 (4–37) | 11 (2–37) |

**POSITION IN LIST OF AUTHORS**

|                        | PRE-2000 | 2000–2009 | 2010 ONWARDS | OVERALL |
|------------------------|----------|-----------|--------------|---------|
| First author number female (%) | 3 (21%)  | 6 (43%)   | 1 (9%)       | 10 (26%) |
| Number resident of research location (%) | 13 (93%) | 14 (100%) | 10 (91%) | 37 (95%) |
| Number national of research location (%) | 12 (86%) | 9 (64%) | 2 (18%) | 23 (59%) |
| Second author number female (%) | 2 (14%)  | 5/13 (38%) | 4 (36%) | 11/38 (29%) |
| Number resident of research location (%) | 12 (86%) | 12/13 (92%) | 10 (91%) | 34/38 (89%) |
| Number national of research location (%) | 12 (86%) | 12/13 (92%) | 8 (73%) | 32/38 (84%) |
| Final author number female (%) | 2 (14%)  | 3 (21%)   | 0           | 5 (13%)  |
| Number resident of research location (%) | 12 (86%) | 10 (71%) | 7 (64%) | 29 (74%) |
| Number national of research location (%) | 12 (86%) | 9 (64%) | 5 (45%) | 26 (67%) |

**OF ALL NAMED AUTHORS**

|                        | Overall | PRE-2000 | 2000–2009 | 2010 ONWARDS |
|------------------------|---------|----------|-----------|--------------|
| Number of named authors | 147 | 116 | 193 | 456 |
| Gender balance number female (%) | 31 (21%) | 44 (38%) | 58 (30%) | 133 (29%) |
| Residence Number resident of research location (%) | 132 (90%) | 99 (85%) | 141 (73%) | 372 (82%) |
| Nationality Number national of research location (%) | 124 (84%) | 88 (76%) | 105 (54%) | 317 (70%) |

**OF ALL NAMED AUTHORISED CATEGORISED BY INCOME STATUS OF RESEARCH LOCATION**

|                        | HIC | LMIC | OVERALL | P value |
|------------------------|-----|------|---------|---------|
| Number of papers       | 11  | 28   | 39      |         |
| Number of named authors | 122 | 334  | 456     |         |
| Gender balance number female (%) | 25 (20%) | 108 (32%) | 133 (29%) | $p = 0.014^*$ |
| Residence Number resident of research location (%) | 122 (100%) | 250 (75%) | 372 (82%) | $p < 0.0001^*$ |
| Nationality Number national of research location (%) | 114 (93%) | 203 (61%) | 317 (70%) | $p < 0.0001^*$ |

HICs, high-income countries; LMICs, low- to middle-income countries.

*Statistically significant.

https://doi.org/10.1371/journal.pntd.0009376.t004
Funding

There were significant missing data related to the funding of trials, particularly the funding amount. Of the 33 trials where data were available, 19 (58%) were funded by a single funder, and 14 (42%) had multiple funders. Thirty-six percent of trials had funding from industry, 67% from government bodies, and 42% from nongovernmental bodies. Twenty-nine (88%) trials were entirely funded by institutions based in HICs, and 4 (12%) were entirely funded by institutions based in LMICs.

Discussion

Our systematic review findings show that HIV-associated CM trials are generally conducted in locations reflecting the global burden of disease. There has been a marked shift from the USA to sub-Saharan Africa over the last 2 decades. CM trials are broadly representative of the patient population, but there is an underrepresentation of very sick patients with a low baseline GCS and those suffering with a relapse of CM. With the change in location from HICs to LMICs, there has been a significant trend for authors to be nonnationals of the country where research is performed, particularly in first and senior author positions. Female authors are generally underrepresented and, again, this is most marked in first and particularly senior author positions.

CM remains a major public health problem, and it is reassuring that the number of trials being performed has remained steady throughout the HIV epidemic. The bulk of CM disease has likely always been in sub-Saharan Africa, and roughly 75% of all CM deaths currently occur in sub-Saharan Africa. As the number of cases of CM reduced in North America and Western Europe, there was a shift in focus to LMICs with a clear desire to identify simpler, less toxic, and more effective treatment regimens for CM. It is therefore appropriate that sub-Saharan Africa is now the epicentre of CM trials, recruiting 76% of all trial participants in the last decade. This is followed by the Asia and Pacific region where 22% of all CM deaths occur and 21% of participants were recruited. This demonstrates that the regional distribution of CM trials is now well matched to the epidemiology and likely mirrors a general increase in funding for global health [64], including HIV research in LMICs [65]. The bulk of research has taken place in a small number of countries (particularly Malawi, South Africa, and Uganda). By studying Fig 2, which compares the number of participants recruited in different countries with data from the global disease burden estimates identifying the 12 countries globally with the largest number of annual cases in 2014, one can see areas with a high burden of disease that have not been involved in clinical trials such as Nigeria, Kenya, and Mozambique. Other countries, such as India for example, have a lot of CM cases but have only recruited a small number of participants into clinical trials. This uneven geographical spread is not unique to CM trials and is reflected in the global distribution of clinical trials more broadly. There are multiple, overlapping reasons for this which include the levels of internal and external funding made available to research and development in a specific country [66]; access to partnerships with other research institutions; experience with clinical research (including having hosted previous CM trials); and the efficiency of the regulatory approval process in country [67].

When considering the participants in CM trials, the proportion who are female, ART experienced, and suffering with severe disease has increased over time. The majority of earlier trials were conducted in HICs where the epidemic particularly affected men who have sex with men, and over time as trials were increasingly conducted in sub-Saharan Africa and the Asia and Pacific region, there has been an increase in the proportion of female participants: 38% of all trial participants recruited since 2010 were female. Men are more likely to be diagnosed with advanced HIV disease, either due to delayed testing or nonadherence to ART and therefore
more likely to develop CM. In routine care conditions, the proportion of CM patients who are female is roughly 40% [16,23,24,68], so although there is no gender parity, the most recent CM trials mirror the general patient population.

CM almost entirely occurs in individuals with very advanced HIV disease (CD4 <100 cells/mm³), and conception is quite rare in this population [69]. Pregnant and breastfeeding women are however most often excluded from CM trials due to a number of reasons. Often there is reluctance from ethics committees to include pregnant women in research studies, and sponsoring institutions may not be willing to take on the risk of litigation in the event of a poor outcome [70]. In addition, there are scientific concerns about antifungal toxicity, particularly with regard to fluconazole as there is weak evidence to suggest it is teratogenic at the high doses given for CM [71,72]. One caveat to this is whereby trials include lactating women who voluntarily stop breastfeeding to participate in the trial and are supplied with formula milk by the research team. In routine care settings, pregnant and lactating women with CM often receive treatment with fluconazole, particularly where this is the only treatment available. The inclusion of pregnant and lactating women in clinical trials is a broad and urgent issue [2,73,74], and there is reassuring evidence to suggest that this deficit is slowly being addressed in HIV-related clinical trials at least. Our research has identified that, out of 5,011 patients who were screened, only 12 were excluded due to pregnancy and 5 due to lactation, so this is not a large population that is being excluded. That does however not negate the need to build an evidence base to guide the management of pregnant and lactating women suffering from this potentially fatal infection. The most comprehensive collection of clinical data on CM in pregnancy is a case series from Uganda [75]. Teams across the globe should strongly consider collecting and combining observational data sets to build a deeper understanding of the safety profile of different treatment regimens and to collate maternal and neonatal outcomes. In addition, pregnant and lactating women should be considered for inclusion in future trials.

Despite allowing treatment-experienced patients (those predominantly on zidovudine monotherapy) to be recruited in the earlier trials in the USA, concerns about ART status and the potential for that to be a confounding factor led to most trials in the 2000s only including ART-naïve patients. These concerns proved to be unfounded, and there has been no difference in outcome observed between these groups [19]. Over the last decade, the number of CM patients who were ART experienced has steadily increased to the current levels seen today of roughly 36% [23,24,26], and clinical trial participation has matched this.

Importantly, almost all trials have excluded patients suffering from a relapse of CM. Only 28 individuals in total were recruited into trials, and these were all before 2000. The rationale for this is that patients may have acquired antifungal resistance and that the induction regimens may not be effective. The 2 largest CM trials conducted in recent years excluded 8% to 9% of all patients screened due to relapse [19,62], and recent published data from routine care settings have shown relapse to occur in roughly 10% of cases [16,23,25,26]. Relapse is therefore relatively common and drug resistance testing is not widely available so this population should be considered for future clinical trials, either among those suffering a first episode or within independent studies.

The methodology adopted in this study can also assist with the planning of future clinical trials and the assumptions that can be made about participant attrition when calculating a sample size. We have learned that it is rare for participants to withdraw their consent (1%) or be lost to follow-up (2%). This likely reflects the fact that CM is a life-threatening condition and clinical trials often provide promising therapies or, particularly in LMICs, a standard of care that is superior to the routine care available. There is extensive literature to demonstrate that individuals with CM who enrol in a clinical trial have a better outcome, regardless of treatment arm [23,76]. The reasons for this include having a dedicated clinical research team who
have more time to care for patients, better monitoring and correction of drug-induced toxicities, and aggressive management of raised intracranial pressure, a common and potentially fatal complication of CM. These quantitative data do not however determine the impact of structural coercion into these trials, nor does it draw on any lived experience of trial participants. This is the focus of our research team who have embedded an ethnographic study into the ongoing AMBIsome Therapy Induction OptimisatioN (AMBITION) study [77].

It is essential to include researchers who are from and/or based in the location where the study is being conducted in a meaningful way. We found that, over time, there was a significant trend of named authors being decreasingly a resident or national of a research site. This finding mirrors the increase in research conducted in LMICs through TRPs and is supported by the significant difference in these 2 domains when comparing trials conducted in HICs and LMICs. This is consistent with broader reviews of global health research in Africa in general which has found that indigenous researchers are frequently "stuck in the middle" [3,15]. For example, Hedt-Gauthier and colleagues found that among general health-related studies published between 2014 and 2016, just 54% of authors were from the country of the paper’s focus and this was 52.9% among the first author. Overall, in this study, we found this to be 70% and 59%, respectively, which is marginally better. There is no doubt that our discipline needs to work much harder to address this inequality, and we acknowledge the authorship of this paper itself lacks the diversity we aspire to. An in-depth discussion is beyond the scope of this article, and we encourage readers to access and actively engage with the growing body of literature on this topic, including discussions on the role of researchers from HICs when it comes to decolonising global health [78–81].

Authorship of CM trial manuscripts was found to have poor representation of female authors. Of all named authors, 29% were female, but a lower proportion were first (26%) and final (13%) author. Although there was no significant change over time, women were better (but still under) represented as authors of trials conducted in LMICs, and as the majority of trials are currently conducted in LMICs, there may be an increase over time. There were however no female authors from LMICs who were listed as the first or final author in the last decade. This finding is consistent with numerous other studies that have found female researchers to be underrepresented in clinical trials and more likely to occupy the middle section of the authorship list [82,83]. This may be partially due to the fact that, in Africa for example, 72% of all physicians are male [84], and in patriarchal societies, female physicians may have competing demands with regard to childcare and family responsibilities [67]. There is an urgent need to ensure female researchers are given the opportunity to gain research experience, be appointed to and supported within senior research roles, and ultimately become eligible for more of the prestigious authorship positions. The Global Health 50/50 initiative provides extensive guidance for individuals and institutions to address gender inequality in the workplace [85].

This is the first systematic review that has described the characteristics of participants in CM interventional trials over time and made a comparison with the general population who develop the disease. There are several limitations to this study. We only included clinical trials in this review, and we acknowledge that clinical trials are not the only useful source of data. There has been a large body of observational work conducted that has informed CM policy which was not included in this review. Observational study participants are more likely to resemble the overall population affected, and, given less stringent requirements in terms of conduct and monitoring, the authors and funders are likely more representative of study locations. There is an urgent need and opportunity with electronic systems to streamline and simplify data collection and monitoring for randomised studies, so that smaller institutions (especially at primary and secondary level) and local investigators are not, in effect, excluded from participation. In addition, there were rare instances where, despite additional efforts, it was not possible to extract data for
all variables from published papers. In particular, the earlier studies did not consistently present full screening information. This resulted in some studies being excluded from specific aspects of the analysis which may have led to an inaccurate overall picture.

This work was motivated by the pursuit of equity in global health research. Although broad reviews and commentaries have highlighted concerns regarding representation and inclusion, it is important to acknowledge that each individual disease tends to have its own tight-knit research community and that there may be considerable heterogeneity between groups. We have presented a comprehensive but simple methodology to describe trends in the representation and inclusion of patients and researchers over time. This methodology can be used to help focus our future efforts as we strive for equity. In addition, we now have the foundation of what can be an ongoing monitoring exercise to map our progress over the coming years. We believe that this methodology could be simply adopted and adapted by other research groups.

Conclusions

HIV-associated CM trials are generally conducted in locations which are heavily affected by the disease. Women and ART-experienced individuals are well represented as participants in clinical trials, but there is an underrepresentation of those with severe CM and those suffering from a relapse. Recent trials have been predominantly conducted in LMICs, and when compared to earlier trials in HICs, there is a tendency for first and senior authors to be nonnational and/or nonresident of the research location. Female researchers are underrepresented in general but particularly as first and senior authors. This paper highlights areas for the CM research community to focus on as we strive for equity.

Key Learning Points

- HIV-associated cryptococcal meningitis remains a significant contributor to AIDS-related mortality, and ongoing clinical trials are needed to improve outcomes.
- Trials for cryptococcal meningitis occurred in high-incidence countries, but some highly affected countries have not hosted trials.
- The sex and antiretroviral therapy status of trial participants matched the general population with cryptococcal meningitis, but individuals with reduced consciousness and those suffering a relapse were underrepresented.
- Women were underrepresented as authors, particularly as first and final authors.
- Compared to trials conducted in high-income countries, trials conducted in low- and medium-income countries were less likely to have authors resident in or nationals of the trial location.

Top Five Papers

1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–8
2. Azzo C, Tsholo K, Tlhako N, Patel RKK, Leeme T, Jarvis JN, et al. High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B-Based Therapy Under Routine Care Conditions in Africa. Open Forum Infect Dis. 2018;5(11).

3. Heyrana K, Byers HM, Stratton P. Increasing the Participation of Pregnant Women in Clinical Trials. JAMA. 2018;320(20):2077–8.

4. Hedt-Gauthier BL, Jeufack HM, Neufeld NH, Alem A, Sauer S, Odhiambo J, et al. Stuck in the middle: a systematic review of authorship in collaborative health research in Africa, 2014–2016. BMJ Glob Health. 2019;4(5):e001853

5. Global Health 50/50. Power, privilege and priorities: the Global Health 50/50 2020 report. 2020.

References

1. Abimbola S. The foreign gaze: authorship in academic global health. BMJ Glob Health. 2019; 4 (5): e002068. https://doi.org/10.1136/bmjgh-2019-002068 PMID: 31750005

2. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues. 2013; 23 (1):e39–45. https://doi.org/10.1016/j.whi.2012.10.003 PMID: 23312713

3. Mbaye R, Gebeyehu R, Hossmann S, Mbarga N, Bih-Neh E, Eteki L, et al. Who is telling the story? A systematic review of authorship for infectious disease research conducted in Africa, 1980–2016. BMJ Glob Health. 2019; 4 (5):e001855. https://doi.org/10.1136/bmjgh-2019-001855 PMID: 31750001

4. Sumathipala A, Siribaddana S, Patel V. Under-representation of developing countries in the research literature: ethical issues arising from a survey of five leading medical journals. BMC Med Ethics. 2004; 5: E5. https://doi.org/10.1186/1472-6939-5-5 PMID: 15461820

5. Ahmad N, Boutron I, Dechartres A, Durieux P, Ravaud P. Geographical Representativeness of Published and Ongoing Randomized Controlled Trials. The Example of: Tobacco Consumption and HIV Infection. PLoS ONE. 2011; 6 (2):e16878. https://doi.org/10.1371/journal.pone.0016878 PMID: 21347383

6. Siegfried N, Clarke M, Volmink J. Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution. BMJ (Clinical research ed). 2005; 331(7519):742. https://doi.org/10.1136/bmj.331.7519.742 PMID: 16195291

7. Zani B, Pienaar ED, Oliver J, Siegfried N. Randomized Controlled Trials of HIV/AIDS Prevention and Treatment in Africa: Results from the Cochrane HIV/AIDS Specialized Register. PLoS ONE. 2011; 6 (12):e28759. https://doi.org/10.1371/journal.pone.0028759 PMID: 22194905

8. Iyer AR. Authorship trends in The Lancet Global Health. Lancet Glob Health. 2018; 6 (2):e142. https://doi.org/10.1016/S2214-109X(17)30497-7 PMID: 29389534

9. UNAIDS. Financing the Response to HIV in Low- and Middle-Income Countries. Geneva: UNAIDS; 2016.

10. Crane J. Scrambling for Africa: AIDS, expertise and the rise of American Global Health science. New York: Cornell University Press; 2013.

11. Baghaei Lakeh A, Ghaffarzadegan N. Global Trends and Regional Variations in Studies of HIV/AIDS. Sci Rep. 2017; 7 (1):4170. https://doi.org/10.1038/s41598-017-04527-6 PMID: 28646150

12. UNAIDS. Seizing The Moment: Tackling entrenched inequalities to end epidemics. Geneva; 2020.

13. Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, et al. Research priorities to inform “Treat All” policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA). J Int AIDS Soc. 2019; 22 (1):e25218. https://doi.org/10.1002/jias.25218 PMID: 30657644

14. Bekker L-G, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International
Equity in HIV-associated cryptococcal meningitis trials

PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009376 May 27, 2021 16 / 19

AIDS Society—Lancet Commission. Lancet. 2018; 392 (10144):312–58. https://doi.org/10.1016/S0140-6736(18)31070-5 PMID: 30032975

15. Hedt-Gauthier BL, Jeufack HM, Neufeld NH, Alem A, Sauer S, Odhiambo J, et al. Stuck in the middle: a systematic review of authorship in collaborative health research in Africa, 2014–2016. BMJ Glob Health. 2019; 4 (5):e001853. https://doi.org/10.1136/bmjgh-2019-001853 PMID: 31750000

16. Tenforde MW, Mokonane M, Leeme T, Patel RKK, Lekwape N, Ramodimoosi C, et al. Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis. Clin Infect Dis. 2017; 65 (5):779–86. https://doi.org/10.1093/cid/cix430 PMID: 28505328

17. Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, et al. The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa. Clin Infect Dis. 2018; 66 (suppl 2):S118–s25. https://doi.org/10.1093/cid/cix1140 PMID: 29514233

18. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17 (8):873–81. https://doi.org/10.1016/S1473-3099(17)30243-8 PMID: 28483415

19. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018; 378 (11):1004–17. https://doi.org/10.1056/NEJMoa1710922 PMID: 29539274

20. Jarvis J, Leeme T, Molefi M, Chofle AA, Bidwell G, Tsholo K, et al. Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial. CID. 2018;published online June 26, 2018.

21. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016; 374 (6):542–54. https://doi.org/10.1056/NEJMoa1509024 PMID: 26663555

22. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation.

23. Patel RKK, Leeme T, Azzo C, Tlhako N, Tsholo K, Tawanana EO, et al. High Mortality in HIV-Associated Cryptococcal Meningitis. PLoS Negl Trop Dis. 2016; 10 (7):e0004865. https://doi.org/10.1371/journal. pntd.0004865 PMID: 27467556

24. Meiring S, Fortuin-de Smidt M, Kularatne R, Dawood H, Prevalence GNP. Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa. PLoS Negl Trop Dis. 2016; 10 (7):e0004865. https://doi.org/10.1371/journal. pntd.0004865 PMID: 27467556

25. Adeyemi BO, Ross A. Management of cryptococcal meningitis in a district hospital in KwaZulu-Natal: a clinical audit. Afr J Prim Health Care Fam Med. 2014; 6 (1):E1–6.

26. Adeyemi B, Ross A. Profile and mortality outcome of patients admitted with cryptococcal meningitis to an urban district hospital in KwaZulu-Natal, South Africa. J Int AIDS Soc. 2014; 17 (4 Suppl 3):19623. https://doi.org/10.7448/IAS.17.4.19623 PMID: 25394127

27. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med. 1990; 113 (3):183–7. https://doi.org/10.1056/NEJM199002283240902 PMID: 1992319

28. Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1991; 324 (9):580–4. https://doi.org/10.1056/NEJM199102283240902 PMID: 1992319

29. de Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JK, van Bokxel CJ, van Ketel RJ, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS (London, England). 1992; 6 (2):185–90. https://doi.org/10.1097/00002030-199202000-00007 PMID: 1313682

30. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992; 326 (2):83–9. https://doi.org/10.1056/NEJM199201093260202 PMID: 1727236

31. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992; 326 (12):793–8. https://doi.org/10.1056/NEJM199203193261203 PMID: 1538722

32. Sharkey PK, Graybill JR, Johnson ES, Haurath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996; 22 (2):315–21. PMID: 8838189
33. Joly V, Aubry P, Ndayiragide A, Carriere I, Kawa E, Milka-Cabanne N, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1996; 23 (3):556–62. https://doi.org/10.1093/clinids/23.3.556 PMID: 8679780

34. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS (London, England). 1997; 11 (12):1463–71. https://doi.org/10.1097/00002030-199712000-00010 PMID: 9342068

35. Chotmongkol V, Sukepanasarncharoen W, Thavomplitaik Y. Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. J Med Assoc Thai = Chotmaihet thangphaet. 1997; 80 (7):416–25. PMID: 9277070

36. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. J Infect Dis. 1997; 137 (1):15–21. https://doi.org/10.1086/515110 PMID: 10064246

37. Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, et al. Combination therapy with flucytosine and amphoter cin B for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. 1998; 26 (6):1362–6. https://doi.org/10.1086/516372 PMID: 9638863

38. Saag MS, Cloud GA, Graybill JR, Tuazon CU, Johnson PC, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999; 28 (2):291–6. https://doi.org/10.1086/337010 PMID: 10064246

39. Newton PN, Thai le H, Tip NQ, Short JM, Chierakul W, Rajanuwong A, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002; 35 (6):769–72. https://doi.org/10.1086/342299 PMID: 12203177

40. Vibhagool A, Sungkunapraph S, Moosikapun P, Chchetbotsakd P, Tansuphaswaswadikul S, Bowonwatanuwon C, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. 2003; 36 (10):1329–31. https://doi.org/10.1086/374849 PMID: 12746781

41. Moosikapun P, Chchetbotsakd P, Anunnatsiri S, Choksawaphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thai = Chotmaihet thangphaet. 2003; 86 (4):293–8. PMID: 12757072

42. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004; 189 (12):2185–91. https://doi.org/10.1086/420829 PMID: 15181565

43. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (London, England). 2004; 363 (9423):1764–7. https://doi.org/10.1016/S0140-6736(04)61630-0 PMID: 15172774

44. Chotmongkol V, Arayawihanont A, Sawanyawisuth K, Thavomplitaik Y. Initial treatment of cryptococcal meningitis in AIDS. Southeast Asian J Trop Med Public Health. 2005; 36 (1):170–3. PMID: 15906662

45. Tansuphaswaswadikul S, Maek-a-Nartawat W, Phonrat B, Boonpokbn L, Mctm AG, Pitisuttithum P. Comparison of one week to two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J Med Assoc Thai = Chotmaihet thangphaet. 2006; 89 (10):1677–85. PMID: 17128844

46. Techapornmooch M, Suankratay C. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial. Scand J Infect Dis. 2007; 39 (10):896–901. https://doi.org/10.1080/00365540701383147 PMID: 17852947

47. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008; 46 (4):393–5. https://doi.org/10.1080/13693780701851695 PMID: 18415850

48. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyal A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008; 47 (1):123–30. https://doi.org/10.1086/588792 PMID: 18505387

49. Pappas PG, Chchetbotsakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009; 48 (12):1775–83. https://doi.org/10.1086/599112 PMID: 19441980
50. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination fluconosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010; 50 (3):338–44. https://doi.org/10.1086/649861 PMID: 20038244

51. Makadzange AT, Ndihovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010; 50 (11):1532–8. https://doi.org/10.1086/652652 PMID: 20415574

52. JadHAV MP, Bamba A, Shinde VM, Gogtay N, Kshirsagar NA, Bichile LS, et al. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial. J Postgrad Med. 2010; 56 (2):71–5. https://doi.org/10.4103/0022-3859.65276 PMID: 20623839

53. Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2009; 51 (2):225–32. https://doi.org/10.1086/598273 PMID: 20536366

54. Loyse A, Wilson D, Meinjtes G, Jarvis JN, Bicanic T, Bishop L, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and fluconosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012; 54 (1):121–8. https://doi.org/10.1093/cid/cjr745 PMID: 22052885

55. Jarvis JN, Meinjtes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (London, England). 2012; 26 (9):1105–13. https://doi.org/10.1097/QAD.0b013e328356a93 https://doi.org/10.1097/QAD.0b013e328356a93 PMID: 22421244

56. Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, et al. A phase II randomized controlled trial adding oral fluconosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS (London, England). 2012; 26 (11):1363–70. https://doi.org/10.1097/QAD.0b013e328354b419 PMID: 22526177

57. Day JN, Chau TT, Laloo D. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013; 368 (26):2522–3.

58. Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013; 56 (8):1165–73. https://doi.org/10.1093/cid/cit019 PMID: 23362285

59. Boulware DR, Meya DB, Muzoora C, Rolifes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014; 370 (26):2487–98. https://doi.org/10.1056/NEJMoa1312884 PMID: 24963568

60. Vaidhya SA, Gupta BB, Jha RK, Kumar R. Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis. J Clin Diagn Res. 2015; 9 (2):Oc14–6. https://doi.org/10.7860/JCDR/2015/12360.5601 PMID: 25854980

61. Villanueva-Lozano H, Trevino-Rangel RJ, Gonzalez GM, Hernandez-Rodriguez PA, Camacho-Ortiz A, Castillo-Reyna L, et al. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience. Infection. 2018; 46 (1):25–30. https://doi.org/10.1007/s15010-017-1059-3 PMID: 28815430

62. Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019; 19 (8):843–51. https://doi.org/10.1016/S1473-3099(19)30127-6 PMID: 31345462

63. Jarvis JN, Leeme TB, Molefi M, Choffe AA, Bidwell G, Tsholo K, et al. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clin Infect Dis. 2019; 68 (3):393–401. https://doi.org/10.1093/cid/ciy515 PMID: 29945252

64. McCoy D, Chand S, Sridhar D. Global health funding: how much, where it comes from and where it goes. Health Policy Plan. 2009; 24 (6):407–17. https://doi.org/10.1093/heapol/czp026 PMID: 19570773

65. Policy Cures Research. SEXUAL AND REPRODUCTIVE HEALTH RESEARCH AND DEVELOPMENT: UNDERSTANDING THE SPECTRUM. Surry Hills, Australia: Policy Cures Research; 2020.

66. Simpkin V, Namubiru-Mwaura E, Clarke L, Mossialos E. Investing in health R&amp;D: where we are, what limits us, and how to make progress in Africa. BMJ Glob Health. 2019; 4 (2):e001047. https://doi.org/10.1136/bmjgh-2018-001047 PMID: 30899571

67. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries- a systematic review. Int J Equity Health. 2018; 17 (1):37. https://doi.org/10.1186/s12939-018-0748-6 PMID: 29566721
68. Kouakou GA, Ello NF, Kassi NA, Keita M, Doumbia A, Mossou C, et al. [Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast]. J Mycol Med. 2017; 27 (1):72–8. French. https://doi.org/10.1016/j.mycolmed.2016.10.001 PMID: 28108201

69. Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004; 103 (4):663–8. https://doi.org/10.1097/01.AOG.0000117083.33239.b5 PMID: 15051556

70. Mastroianni AC, Henry LM, Robinson D, Bailey T, Faden RR, Little MO, et al. Research with Pregnant Women: New Insights on Legal Decision-Making. Hastings Cent Rep. 2017; 47 (3):38–45. https://doi.org/10.1002/hast.706 PMID: 28543423

71. Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2014; 70 (1):14–22. https://doi.org/10.1093/jac/dku355 PMID: 25204341

72. Wickremesinhe MN, Little MO, Carter AS, Sullivan KA, Lyerly AD. Beyond “Vessels and Vectors”: A Global Review of Registered HIV-Related Clinical Trials with Pregnant Women. J Womens Health (Larchmt). 2019; 28 (1):93–9.

73. Heyrana K, Byers HM, Stratton P. Increasing the Participation of Pregnant Women in Clinical Trials. JAMA. 2018; 320 (20):2077–8. https://doi.org/10.1001/jama.2018.17716 PMID: 30422300

74. Little MO, Wickremesinhe MN. Research with pregnant women: a call to action. Reprod Health. 2017; 14 (3):156. https://doi.org/10.1186/s12978-017-0419-x PMID: 29297373

75. Pastick KA, Nalintya E, Tugume L, Ssebambulidde K, Stephens N, Evans EE, et al. Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. Med Mycol. 2019; 58 (3):282–92.

76. Tenforde MW, Gertz AM, Lawrence DS, Wills NK, Guthrie BL, Farquhar C, et al. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2020; 23 (1):e25416. https://doi.org/10.1002/jia2.25416 PMID: 31957332

77. Lawrence DS, Youssouf N, Molloy SF, Alano A, Alunandika M, Boulware DR, et al. AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018; 19 (1):649. https://doi.org/10.1186/s13063-018-3026-4 PMID: 30470259

78. Lawrence DS, Hirsch LA. Decolonising global health: transnational research partnerships under the spotlight. Int Health. 2020; 12 (6):518–23. https://doi.org/10.1093/inthealth/ihaa073 PMID: 33165557

79. Tuck E, Yang KW. Decolonization is not a metaphor. Decolonization: Indigeneity, Education. Society. 2012; 1 (1):1–40.

80. Affun-Adegbulu C, Adegbulu O. Decolonising Global (Public) Health: from Western universalism to Global pluriversalities. BMJ Glob Health. 2020; 5 (8):e002947. https://doi.org/10.1136/bmjgh-2020-002947 PMID: 32819916

81. Abimbola S. On the meaning of global health and the role of global health journals. Int Health. 2018; 10 (2):63–5. https://doi.org/10.1093/inthealth/ihy010 PMID: 29528402

82. Pinho-Gomes A-C, Peters S, Thompson K, Hockham C, Ripullone K, Woodward M, et al. Where are the women? Gender inequalities in COVID-19 research authorship. BMJ Glob Health. 2020; 5 (7):e002922. https://doi.org/10.1136/bmjgh-2020-002922 PMID: 32527733

83. Filardo G, da Graca B, Sass DM, Pollock BD, Smith EB, Martinez MA-M. Trends and comparison of female first authorship in high impact medical journals: observational study (1994–2014). BMJ (Clinical research ed). 2016; i847:352.

84. Boniol M, McIlsaac M, Xu L, Wuliji T, Diallo K, Campbell J. Gender equity in the health workforce: analysis of 104 countries. Geneva: World Health Organisation; 2019. Contract No.: WHO/HIS/HWF/Gender/WP1/2019.1.

85. Global Health 50/50. Power, privilege and priorities: the Global Health 50/50 2020 report.; 2020.